Datapoint: GSK Expands Jemperli’s Oncology Reach
The FDA last week granted accelerated approval to GlaxoSmithKline’s Jemperli for the treatment of mismatch repair deficient (dMMR) solid tumors that have progressed despite previous treatment. The PD-1 drug was initially approved in April 2021 for previously treated dMMR endometrial cancer. It holds 55% covered or better status under the medical benefit, and 18% covered or better status under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 8/23/21